Suit Challenges USPTO Decision On Biotech Dispute

Law360, New York (November 28, 2005, 12:00 AM EST) -- Seeking to overturn a decision by the U.S. Patent and Trademark Office, Danish biotechnology company Novozymes AS has sued its primary rival Genencor International Inc. in federal court in a challenge to Genencor’s patent priority dates.

In the complaint, Novozymes asserts the USPTO’s Board of Patent Appeals and Interferences erred in its interpretation of the enzyme-producing technology and disregarded key requirements for construing interference counts.

As a result, the earliest invention date was mistakenly granted in late September to Genencor’s scientists, according to the suit filed...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.